Drug Profile
AS 602868
Alternative Names: AS 2868; AS602868; CDC 839; SPC-839Latest Information Update: 05 Mar 2008
Price :
$50
*
At a glance
- Originator Merck Serono; Signal Research Division
- Class Anti-inflammatories; Antirheumatics; Pyrimidines; Small molecules
- Mechanism of Action I-kappa B kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haematological malignancies; Inflammation
Most Recent Events
- 18 Feb 2008 Discontinued - Phase-I for Haematological malignancies in USA (PO)
- 18 Feb 2008 Discontinued - Preclinical for Inflammation in USA (PO)
- 29 Oct 2007 No development reported - Preclinical for Inflammation in USA (PO)